Japan’s IPR Text Flagged Ahead of Asian Trade Meet
This article was originally published in PharmAsia News
Just ahead of a meeting of participating countries of the Asian Regional Comprehensive Economic Partnership (RCEP) in Myanmar, pro-health groups have cautioned India about "speedily" tabled intellectual property rights (IPR)-related proposals by Japan, which they claim could undermine public health safeguards in India's patent law.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.